THE MUST-HAVE COLLABORATIONS FOR SUCCESSFUL DRUG DEVELOPMENT

Collaborations among academic and government researchers, pharmaceutical and biotechnology companies, regulatory agencies, and patients and their families are crucial to research and development of therapeutics for rare diseases. Industry, academic and government researchers, regulatory agencies, patients and their caregivers all confront challenges in today’s environment for therapeutic development. As a result, the stakeholders are realizing increasing value in collaborations, which can help tackle these challenges.

Spotlight

Medicago

Medicago is a clinical-stage biopharmaceutical company developing novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide.

OTHER WHITEPAPERS
news image

BIOTECHNOLOGY UPDATE

whitePaper | April 24, 2022

The Global Forum on Biotechnology, established in 2010, is one of 15 Global Fora created by OECD Committees. Global Fora are not official OECD bodiesbut are best described as broad.

Read More
news image

Covid-19 Vaccine Distribution System

whitePaper | April 14, 2021

Delivering Covid-19 vaccines to 7.8 billion people is a daunting challenge that will stretch supply chains past their limits. Even if all the needed doses were ready today, vaccine manufacturers still must find solutions to deliver multiple doses of those vaccines to most people on the planet. To read more, please download this free white paper.

Read More
news image

Cell and Gene Therapy Clinical Trials

whitePaper | November 8, 2022

Using experienced-based best practices and documented tools, ICON has conducted over 63 CGT trials across multiple therapeutic areas from haematology-oncology torare and orphan diseases.

Read More
news image

bFGF Supports Human ES Cell Self-Renewal

whitePaper | March 24, 2023

Basic fibroblast growth factor (bFGF) is an important cytokine used to support the growth and self renewal of human embryonic stem cells.

Read More
news image

Enabling the Future of Cell & Gene Therapies through Non Proprietary Patient-Owned Data Collection

whitePaper | March 16, 2021

Cell and gene therapies have emerged as a new treatment paradigm, and with them has come the potential to alter the course of many rare diseases. In many cases, there is an opportunity to correct the underlying dysfunction with a one-time administration of a therapy and provide either a functional cure or a substantial improvement in health outcomes. In other cases, long term symptom relief will be the primary therapeutic objective. Some of these indications may require more than one dose to achieve continued symptom relief and scientists and companies are working on technologies that will enable the use of a repeat dose.

Read More
news image

Transforming cell & gene therapy manufacturing

whitePaper | February 25, 2022

Digitalization and automation promise a better way to streamline the transfer of cell and gene therapies from drug discovery – to commercial production.

Read More

Spotlight

Medicago

Medicago is a clinical-stage biopharmaceutical company developing novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide.

Events